FIND A SOLUTION THAT'S AS
UNIQUE AS YOUR CANCER.
Onconomics Plus offers personalised precision care because every cancer is different.
What is OncoNomics Plus?
Onconomics Plus is a test that shows you how effective specific anti-cancer drugs, targeted therapies and natural treatments are on your individual cancer cells.
It provides you and your physician a comprehensive breakdown of the most suitable and successful treatments for cancer that's personalised to you.
OncoNomics Plus employs a liquid biopsy where a blood test offers a less invasive, and faster alternative to traditional tissue biopsies.
It's also highly sensitive in detecting cancer-related genetic changes - it offers real-time monitoring and tracking cancer progression or mutations.
Comprehensive Library of Tested Agents
Not sure if your cancer's resistant to Cisplatin or sensitive to Gemcitabine?
OncoNomics Plus has a wide drug library that helps identify the most suitable cancer drugs according to your genomics(?).
The test measures the CTC count in the blood. Doing so helps clinicians and patients understand the progression of cancer and treatment response.
Assesses the genetic expressions of cancer to reveal the resistance and sensitivity of cancer cells, therefore personalising treatment plans.
Onconomics tests over 50+ chemotherapeutic substances and 60+ targeted drugs, determining whether the chemotherapeutic agent will work for a specific cancer of the patient, whilst helping to identify the most suitable treatment.
While many natural substances are known to have cancer-targeting properties, not all substances work equally for every patient. Onconomics panel tests over 50 natural substances to offer evidence-based recommendations on ones with best yield.
We also run the Safety Check (ChemoSNiP) to assess your body's
ability to metabolize and detoxify specific drugs
RGCC provides a comprehensive range of tests designed to detect, analyze, and screen cancer cells. Our current portfolio includes tests capable of identifying potential early signs of cancer, monitoring diagnosed cancers, and offering personalized guidance on the most effective combinations of cancer treatments and therapies, including complementary approaches.
RGCC can detect all types of cancer except brain and CNS (central nervous system) cancers.
Certainly, patients with lymphoma or leukemia can utilize an RGCC test to measure the number of circulating tumor cells (CTC) they have.
Oncocount, Oncotrace or Oncotrail tests are useful in the follow up and monitoring of specific types of tumors.
